Preview: Startup Lands $140 Million

June 18, 2021

Capsida Biotherapeutics has emerged from stealth mode with a Series A investment and collaborative agreement together worth $140 million.The Newbury Park biotech firm secured funding from Versant Ventures and Westlake Village BioPartners worth $50 million, alongside a $90 million collaboration with Chicago-based pharma giant AbbVie.Capsida focuses on creating gene therapies.Read the full story in the June 21 issue of the San Fernando Valley Business Journal.

Preview: Galpin Ford Prepares to Sell Lightning Pickup

Startup Lands $140 Million

Antonio Pequeño IV

Antonio “Tony” Pequeño IV is a reporter covering health care, finance and law for the San Fernando Valley Business Journal. He specializes in reporting on some of the biggest names in the Valley’s biotechnology sector. In addition to his work with the Business Journal, Tony has reported with BuzzFeed News on the unsupervised use of Clearview AI, a controversial facial recognition technology. Tony, who also conducts freelance reporting, graduated from the USC’s Master of Science in Journalism program in 2021. He is in his fifth year as a journalist as of 2021.

Preview: Startup Lands $140 Million

Featured Articles

ServiceTitan Adds Another Contractor Partner

Evite Scores a Growth Investment

Phonexa Helps With FCC Rules

Related Articles

ServiceTitan Adds Another Contractor Partner

Evite Scores a Growth Investment

Phonexa Helps With FCC Rules

Valley-Area Advertising Agency Sells, Will Merge

Business Events Calendar

ADVERTISE WITH US

ABOUT US

Membership Center

OTHER JOURNALS